extraction_prompts
{'Reason_for_Visit': '
TASK: Extract 'Reason for Visit'.
Respond *only* with a JSON object using this exact schema:
{
"Patient type": "either New patient or follow up"
"second opinion": "whether the visit is consultation/second opinion or not",
"in-person":" either Televisit or in-person. (note, video consult, televisit, telehealth are the same thing",
"summary": "A brief summary of the reason for visit."
}
', 'What_We_Found': '
TASK: Extract 'What We Found'. 
Respond *only* with a JSON object using this exact schema:
{
"Type_of_Cancer": "list the type of cancer"
"Stage_of_Cancer": "list the stage if it is written in the note",
"Distant Metastasis": "if there is distant metastasis (met)." "Yes, to where; No, local, not sure, need more evidence such as imaging.",
"Metastasis": "if there is met, Yes (to where), No, or Not sure",
"lab_summary": "Summary of key lab results.",
"findings": "Summary of new findings or disease status."
}
', 'Treatment_Summary': '
TASK: Extract 'Treatment Summary'. 
Respond *only* with a JSON object using this exact schema:
{
"current_meds": "List of current oncologic medications or regimens.",
"recent_changes": "Any holds, dose reductions, or switches.",
"supportive_meds": "List of supportive medications."
}
', 'Goals of care': '
TASK: Extract 'What We Discussed / Decided'.
Respond *only* with a JSON object using this exact schema:
{
"goals_of_treatment": "eg, cancer is not curable, but it's treatable and the goal is to extend the duration and maintain the quality of life",
"response_assessment": "How the cancer is responding to the treatment, not responding or responding.",
}
'}
============================================================
plan_extraction_prompts
{'Medication_Plan_chatgpt': '
TASK: Extract the 'Medication Plan' from the given 'Assessment/Plan' section.
Include all current and future medication plans for both cancer therapy and supportive treatment. Cancer treatment could be one or many in chemotherapy, hormonal therapy, bone therapy, radiotherapy (eg. rad onc, xrt). Supportive treatment could be one or many in bowel regimen, pain medication, psychiatry medication, neuropathy or any blood transfusion plan. 

Include whether a medication is being started now (e.g,“will start”, “Rx sent”, “starting today” ), plan or discuss in the future after certain condition (e.g., “plan to start after radiation”, “discussed addition of…”), continue or maintained(“continue”), stop or change.

Include an alterative, second-line or clinical trials options if dicussed. 
Include an 'other treatment' section for any other medications that only briefly mentioned in the plan section.
Respond *only* with a JSON object using this exact schema:
{
    "The medication/treatment, one of chemotherapy, hormonal therapy, bone therapy, radiotherapy": 
{"summary":"the summary of this type of medication, including start/stop/cotinue if applicable",
"Short term side_effects_discussed": "short term Side effects of this particular medications.",
"Long term side_effects_discussed": "long term Side effects of this particular medications.."}
}
', 'Medication_Plan': '
TASK: Extract the 'Medication Plan' from the given 'Assessment/Plan' section.
Include future medication plans, changes to current meds (start, stop, continue), supportive meds, bowel regimen, and any blood transfusion plan. Do not include past medications.
Respond *only* with a JSON object using this exact schema:
{
    "medication_plan": "A summary of the complete medication plan."
}
', 'Therapy plan': '
TASK: Extract the 'therapy Plan' from the given 'Assessment/Plan' section.
Include chemotherapy, radiotherapy, hormonal therapy, and bone-therapy plans. Include future plans, changes to current therapy (start, stop, continue). Do not include past therapies.
Respond *only* with a JSON object using this exact schema:
{
    "therapy_plan": "A summary of the complete therapy plan."
}
', 'radiotherapy plan': "
TASK: Extract the 'radiotherapy Plan' from the given 'Assessment/Plan' section.
For radiotherapy, include ANY statement that indicates 
it is being considered, recommended, or may be used, even if no explicit
start/continue/plan keywords are present.
", 'Procedure_Plan': '
TASK: Extract the 'Procedure Plan' from the given 'Assessment/Plan' section.
Include future procedures including surgery, radiation therapy, or interventional procedures such as biopsy, lumbar puncture, or Chemo Port Insertion. Do not include past procedures.
Do not include imaging plan, lab plan, or medication plan.
Respond *only* with a JSON object using this exact schema:
{
    "procedure_plan": "A summary of any planned procedures."
}
', 'Imaging Plan': '
TASK: Extract the 'Imaging Plan' from the given 'Assessment/Plan' section.
Include all future imaging like CT, MRI, PET/CT, ultrasound,  DEXA scans, including timing and rationale if mentioned.
Do not include any procedure plan, lab plan, or medication plan. Do not include past Imaging.
Respond *only* with a JSON object using this exact schema:
{
    "imaging_plan": "A summary of any planned procedures."
}
', 'Lab Plan': '
TASK: Extract the 'lab Plan' from the given 'Assessment/Plan' section.
Include future labs like CBC, CMP, tumor markers, coagulation profile. Specify frequency and rationale if mentioned.
Do not include any procedure plan, medication plan, or imagining plan. Do not include past labs.
Respond *only* with a JSON object using this exact schema:
{
    "lab_plan": "A summary of the future lab plan."
}
', 'Genetic_Testing_Plan': '
TASK: Extract the 'Genetic Testing Plan' from the given 'Assessment/Plan' section.

1. Scope of section:
- First, find the 'Assessment/Plan' section of the note (usually the final section).
- Only look for plans that are clearly about FUTURE genetic or molecular TESTING.

2. What COUNTS as 'genetic or molecular testing':
- Diagnostic, prognostic, or predictive laboratory assays, such as:
  - Tumor genomic sequencing / NGS / panel testing
  - Germline genetic panels (e.g., hereditary cancer panel, BRCA testing)
  - Liquid biopsy / circulating tumor DNA (ctDNA) tests
  - Specific biomarker tests (e.g., PD-L1 testing, MSI testing, EGFR mutation testing)
  - Any plan to "send", "order", "check", or "obtain" a genetic, genomic, or molecular TEST

3. What MUST be EXCLUDED:
- DO NOT include any medications, systemic therapies, or treatment plans:
  - Chemotherapy, immunotherapy, targeted therapies (e.g., FGFR inhibitor, PARP inhibitor, CDK4/6 inhibitor, TKIs)
  - Hormonal therapy, radiation therapy, surgery
  - Clinical trial options, even if the trial involves targeted drugs or inhibitors
- DO NOT include tests that are already completed, historic, or only mentioned in past oncology history.
- DO NOT include imaging (CT, PET, MRI, X-ray, ultrasound) or routine labs (CBC, CMP).

4. If there is NO new genetic or molecular test planned in the Assessment/Plan:
- Set the value to a clear negative statement, for example:
  "No new genetic or molecular tests were planned during this visit."

5. Output format:
Respond *only* with a JSON object using this exact schema:
{
    "genetic_testing_plan": "A summary of any future planned genetic or molecular tests, or a clear statement that none are planned."
}
', 'Referral': '
TASK: Extract 'Referral' from the given 'Assessment/Plan' section.

Respond *only* with a JSON object using this exact schema:
{
"Nutrition": "any nutration referrals such as diet optimization, appetite, weight maintenance), "Genetics": "eg, germline testing, family counseling",
"Specialty": "eg, Palliative care (symptom or pain management, goals of care), Radiation oncology, surgical oncology, Psychology, psychiatry for coping and mood support",
"Others": "Physical or occupational therapy, Social work, financial counseling",
"follow up": "follow up mentioned in the provided text. f/up[, f/p and fup all mean follow up."
}
', 'follow up/next visit': '
TASK: Extract the 'follow up/next visit' from the given 'Assessment/Plan' section.

Respond *only* with a JSON object using this exact schema:
{
    "Next clinic visit": "(in-person or telehealth): timing and purpose"
}
', 'Advance care planning': '
TASK: Extract the 'Advance care planning' from the given 'Assessment/Plan' section.
Include Advance directives, health-care proxy, code status (if appropriate)、
Respond *only* with a JSON object using this exact schema:
{
    "Advance care": "A summary of any planned Advance care."
}
'}
============================================================
explain_prompts
{'Why you came today': "
TASK: Briefly state the purpose of today's visit using only information from the key points. 
", 'What you told us': '
TASK: List the patient concerns, symptoms, or questions mentioned in the NOTE section.
', 'What did we find': "
TASK: Explain the result of today's visit (exam, blood work, scans) in plain language. You need to include all 'key points' from KEYPOINTS section.

", 'What is the plan': '
TASK: List the next steps (treatment, monitoring, follow-up) in plain language. Include all related information from KEYPOINTS section if the following are mentioned, including:
    1, Medication plan
    2, Procedure plan
    3, Imaging plan
    4, Lab plan
    5, Genetic Testing Plan
    6, Referral
', 'Closing with Support': '
TASK: write an ending sentence to show your support. Limit to one sentence maximum.
'}
============================================================











============================================================
RESULTS FOR ROW 45
============================================================

--- Column: coral_idx ---
184

--- Column: note_text ---
"Medical Oncology Consult Note  Video Consult    Patient Name: ***** *****-*****   ***** MRN:  *****   Patient DOB:  07/23/1984   Date of Visit:  04/16/2022  Provider:  ***** ***** *****  Primary Care Provider:  None Per Patient Provider  Referring MD:        Reason for visit:   Chief Complaint   Patient presents with   \u0007 New Patient Evaluation       Diagnosis:    1. Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor negative (CMS code)         I have collected verbal consent for care and acknowledgement of patient financial responsibility at the outset of this video encounter.    History of Present Illness:     37 year old female with a self palpated right T2N1 triple negative breast cancer treated with ***** Taxol ***** ***** . She did not complete taxol but had the equivalent of August 08 weeks. She reports the cancer was growing on the taxol. She went to surgery October 2020 and had a right lumpectomy and *****/ALND.  She had 3 cm of IDC, February 09 ***** positive *****, *****% PR and her 2 negative.   She had radiation and started on xeloda February 2021.  A CT of the chest was done December 2021 and biopsy February 18 showed metastatic breast cancer to lung. She has bilateral lung nodules and right hilar LN.  She has had no treatment since January 2022 when diagnosed with metastatic disease.  She is here for a second opinion.   Her tumor is ***** positive at 10%.  We discussed keynote 355 with gemzar, carboplatin and *****.  We discussed ***** for second line and a clinical trial with a FGFR inhibitor in the future.    Her genetic testing was negative so she does not qualify for a PARP inhibitor.  I encouraged her to start on treatment asap.  We discussed how metastatic triple negative breast cancer is not curable.     Oncologic history    Stage at *****:  Cancer Staging  Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor negative (CMS code)  Staging form: Breast, AJCC 8th \n Edition  - Clinical: Stage IIIB (*****, *****, *****, *****, ER-, PR-, *****-) - Signed by ***** ***** *****, MD on 04/16/2022      Medications:  No current outpatient medications on file.   Reishi mushroom   Papaya enzymes  ***** /sea *****  mullein extract      Allergies: Allergies/Contraindications  No Known Allergies    Medical History:   Past Medical History:   Diagnosis Date   \u0007 Autism    \u0007 GERD (gastroesophageal reflux disease)        Surgical History:   Past Surgical History:   Procedure Laterality Date   \u0007 BREAST SURGERY Right     lumpectomy and *****/ALND       Social History:   Social History     Tobacco Use   \u0007 Smoking status: Never Smoker   \u0007 Smokeless tobacco: Never Used   Substance and Sexual Activity   \u0007 Alcohol use: Not Currently   \u0007 Drug use: Yes     Types: *****   \u0007 Sexual activity: Yes     Partners: Female     Birth control/protection: None   Social History Narrative   \u0007 Not on file       *****:  ***** ***** ***** ***** *****, ***** ***** *****.  *****. *****.     ***** Status: single but has a *****. Lesbian.    Gynecologic History:  G 0 P 0 AB 0    Menarche 11  Premenopausal    OCP 0 years    Fertility treatments 0    Family History:    Family History   Problem Relation Name Age of Onset   \u0007 Pancreatic cancer Maternal Grandmother     \u0007 Testicular cancer Maternal Grandfather                 Review of systems:  CONSTITUTIONAL: No fevers, chills, night sweats, loss of appetite or weight loss  H/E/N/T:  No headaches, vision changes, mouth sores  CV: No *****, orthopnea  PULM: No cough, hemoptysis or sob.   ABD:  No abdominal pain, nausea, vomiting, diarrhea, or bleeding + gerd  GU:  No dysuria or hematuria  SKIN:  No rash or bruising  NEURO:  No difficulty with speech, balance, or gait, no headache  MUSC:  No joint pain  PSYCH:  No depression, or anxiety or trouble sleeping.     Pain    Pain Score/Location    04/16/22 0757   *****:  0     Code status: full code    Performance \n status:  0 - Asymptomatic    Physical exam:  There were no vitals taken for this visit.  GEN: No acute distress, awake and alert, appears stated age    Labs:    No visits with results within 1 Month(s) from this visit.   Latest known visit with results is:   No results found for any previous visit.        Psychologic/emotional well-being/support  She has good support.     Assessment / Plan:    1.  Metastatic triple negative breast cancer to the lung and right hilar lymph node diagnosed January 2022.   2.  Stage IIIB right breast triple negative breast cancer s/p dd AC x 4 and 8 weeks of taxol.  She had progression on taxol and went to surgery October 2020 with a lumpectomy and *****/ALND.  She had 3 cm of residual disease with 2 lymph nodes positive.  She had adjuvant radiation and xeloda.   3.  We discussed how metastatic breast cancer is not curable but is treatable.  I recommend starting on *****, gemzar carboplatin asap.  Second line she could use ***** and there are clinical trials ( such as a FGFR inhibitor)  or other ***** ( such as eribulin or doxil)  for more advanced line treatment.    4. All questions were answered.    5.  We discussed lifestyle modifications to decrease the risk of recurrence as well as primary cancer risk reduction.  I recommend an anti inflammatory and /or diabetes risk reducing diet , limiting alcohol, exercise, stress reduction and sleep management.     ***** ***** *****, MD  Medical Oncology/Hematology    TIME SPENT: I spent a total of 69 minutes on this patient's care on the day of their visit excluding time spent related to any billed procedures. This time includes face-to-face time with the patient as well as time spent documenting in the medical record, reviewing patient's records and tests, obtaining history, placing orders, communicating with other healthcare professionals, counseling the patient, family, or caregiver, and/or care coordination for the diagnoses \n above.      I performed this evaluation using real-time telehealth tools, including a live video Zoom connection between my location and the patient's location. Prior to initiating, the patient consented to perform this evaluation using telehealth tools.              \n"

--- Column: assesment_and_plan ---
"Assessment/Plan:    1.  Metastatic triple negative breast cancer to the lung and right hilar lymph node diagnosed January 2022.   2.  Stage IIIB right breast triple negative breast cancer s/p dd AC x 4 and 8 weeks of taxol.  She had progression on taxol and went to surgery October 2020 with a lumpectomy and *****/ALND.  She had 3 cm of residual disease with 2 lymph nodes positive.  She had adjuvant radiation and xeloda.   3.  We discussed how metastatic breast cancer is not curable but is treatable.  I recommend starting on *****, gemzar carboplatin asap.  Second line she could use ***** and there are clinical trials ( such as a FGFR inhibitor)  or other ***** ( such as eribulin or doxil)  for more advanced line treatment.    4. All questions were answered.    5.  We discussed lifestyle modifications to decrease the risk of recurrence as well as primary cancer risk reduction.  I recommend an anti inflammatory and /or diabetes risk reducing diet, limiting alcohol, exercise, stress reduction and sleep management.     ***** ***** *****, MD  Medical Oncology/Hematology    TIME SPENT: I spent a total of 69 minutes on this patient's care on the day of their visit excluding time spent related to any billed procedures. This time includes face-to-face time with the patient as well as time spent documenting in the medical record, reviewing patient's records and tests, obtaining history, placing orders, communicating with other healthcare professionals, counseling the patient, family, or caregiver, and/or care coordination for the diagnoses \n above.      I performed this evaluation using real-time telehealth tools, including a live video Zoom connection between my location and the patient's location. Prior to initiating, the patient consented to perform this evaluation using telehealth tools.              \n\n\nAssessment/Plan:    1.  Metastatic triple negative breast cancer to the lung and right hilar lymph node diagnosed January 2022.   2.  Stage IIIB right breast triple negative breast cancer s/p dd AC x 4 and 8 weeks of taxol.  She had progression on taxol and went to surgery October 2020 with a lumpectomy and *****/ALND.  She had 3 cm of residual disease with 2 lymph nodes positive.  She had adjuvant radiation and xeloda.   3.  We discussed how metastatic breast cancer is not curable but is treatable.  I recommend starting on *****, gemzar carboplatin asap.  Second line she could use ***** and there are clinical trials ( such as a FGFR inhibitor)  or other ***** ( such as eribulin or doxil)  for more advanced line treatment.    4. All questions were answered.    5.  We discussed lifestyle modifications to decrease the risk of recurrence as well as primary cancer risk reduction.  I recommend an anti inflammatory and /or diabetes risk reducing diet, limiting alcohol, exercise, stress reduction and sleep management.     ***** ***** *****, MD  Medical Oncology/Hematology    TIME SPENT: I spent a total of 69 minutes on this patient's care on the day of their visit excluding time spent related to any billed procedures. This time includes face-to-face time with the patient as well as time spent documenting in the medical record, reviewing patient's records and tests, obtaining history, placing orders, communicating with other healthcare professionals, counseling the patient, family, or caregiver, and/or care coordination for the diagnoses \n above.      I performed this evaluation using real-time telehealth tools, including a live video Zoom connection between my location and the patient's location. Prior to initiating, the patient consented to perform this evaluation using telehealth tools.              \n\n\nAssessment/Plan:    1.  Metastatic triple negative breast cancer to the lung and right hilar lymph node diagnosed January 2022.   2.  Stage IIIB right breast triple negative breast cancer s/p dd AC x 4 and 8 weeks of taxol.  She had progression on taxol and went to surgery October 2020 with a lumpectomy and *****/ALND.  She had 3 cm of residual disease with 2 lymph nodes positive.  She had adjuvant radiation and xeloda.   3.  We discussed how metastatic breast cancer is not curable but is treatable.  I recommend starting on *****, gemzar carboplatin asap.  Second line she could use ***** and there are clinical trials ( such as a FGFR inhibitor)  or other ***** ( such as eribulin or doxil)  for more advanced line treatment.    4. All questions were answered.    5.  We discussed lifestyle modifications to decrease the risk of recurrence as well as primary cancer risk reduction.  I recommend an anti inflammatory and /or diabetes risk reducing diet, limiting alcohol, exercise, stress reduction and sleep management.     ***** ***** *****, MD  Medical Oncology/Hematology    TIME SPENT: I spent a total of 69 minutes on this patient's care on the day of their visit excluding time spent related to any billed procedures. This time includes face-to-face time with the patient as well as time spent documenting in the medical record, reviewing patient's records and tests, obtaining history, placing orders, communicating with other healthcare professionals, counseling the patient, family, or caregiver, and/or care coordination for the diagnoses \n above.      I performed this evaluation using real-time telehealth tools, including a live video Zoom connection between my location and the patient's location. Prior to initiating, the patient consented to perform this evaluation using telehealth tools.              \n\n\nAssessment/Plan:    1.  Metastatic triple negative breast cancer to the lung and right hilar lymph node diagnosed January 2022.   2.  Stage IIIB right breast triple negative breast cancer s/p dd AC x 4 and 8 weeks of taxol.  She had progression on taxol and went to surgery October 2020 with a lumpectomy and *****/ALND.  She had 3 cm of residual disease with 2 lymph nodes positive.  She had adjuvant radiation and xeloda.   3.  We discussed how metastatic breast cancer is not curable but is treatable.  I recommend starting on *****, gemzar carboplatin asap.  Second line she could use ***** and there are clinical trials ( such as a FGFR inhibitor)  or other ***** ( such as eribulin or doxil)  for more advanced line treatment.    4. All questions were answered.    5.  We discussed lifestyle modifications to decrease the risk of recurrence as well as primary cancer risk reduction.  I recommend an anti inflammatory and /or diabetes risk reducing diet, limiting alcohol, exercise, stress reduction and sleep management.     ***** ***** *****, MD  Medical Oncology/Hematology    TIME SPENT: I spent a total of 69 minutes on this patient's care on the day of their visit excluding time spent related to any billed procedures. This time includes face-to-face time with the patient as well as time spent documenting in the medical record, reviewing patient's records and tests, obtaining history, placing orders, communicating with other healthcare professionals, counseling the patient, family, or caregiver, and/or care coordination for the diagnoses \n above.      I performed this evaluation using real-time telehealth tools, including a live video Zoom connection between my location and the patient's location. Prior to initiating, the patient consented to perform this evaluation using telehealth tools.              \n\n\nAssessment/Plan:    1.  Metastatic triple negative breast cancer to the lung and right hilar lymph node diagnosed January 2022.   2.  Stage IIIB right breast triple negative breast cancer s/p dd AC x 4 and 8 weeks of taxol.  She had progression on taxol and went to surgery October 2020 with a lumpectomy and *****/ALND.  She had 3 cm of residual disease with 2 lymph nodes positive.  She had adjuvant radiation and xeloda.   3.  We discussed how metastatic breast cancer is not curable but is treatable.  I recommend starting on *****, gemzar carboplatin asap.  Second line she could use ***** and there are clinical trials ( such as a FGFR inhibitor)  or other ***** ( such as eribulin or doxil)  for more advanced line treatment.    4. All questions were answered.    5.  We discussed lifestyle modifications to decrease the risk of recurrence as well as primary cancer risk reduction.  I recommend an anti inflammatory and /or diabetes risk reducing diet, limiting alcohol, exercise, stress reduction and sleep management.     ***** ***** *****, MD  Medical Oncology/Hematology    TIME SPENT: I spent a total of 69 minutes on this patient's care on the day of their visit excluding time spent related to any billed procedures. This time includes face-to-face time with the patient as well as time spent documenting in the medical record, reviewing patient's records and tests, obtaining history, placing orders, communicating with other healthcare professionals, counseling the patient, family, or caregiver, and/or care coordination for the diagnoses \n above.      I performed this evaluation using real-time telehealth tools, including a live video Zoom connection between my location and the patient's location. Prior to initiating, the patient consented to perform this evaluation using telehealth tools.              \n\n\nAssessment/Plan:    1.  Metastatic triple negative breast cancer to the lung and right hilar lymph node diagnosed January 2022.   2.  Stage IIIB right breast triple negative breast cancer s/p"

--- Column: keypoints ---
{
  "Reason_for_Visit": {
    "Patient type": "New patient",
    "second opinion": "Yes",
    "in-person": "Televisit"
  },
  "What_We_Found": {
    "Type_of_Cancer": "Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor negative",
    "Stage_of_Cancer": "Stage IIIB",
    "Distant_Metastasis": "Yes, to the lung and right hilar lymph node",
    "Metastasis": "Yes, to the lung and right hilar lymph node"
  },
  "Treatment_Summary": {
    "current_meds": "Xeloda",
    "supportive_meds": "Reishi mushroom, Papaya enzymes, Mullein extract"
  },
  "Goals of care": {
    "response_assessment": "We discussed how the cancer is not responding to the current treatment (taxol) and the patient has had progression."
  },
  "Medication_Plan_chatgpt": {
    "chemotherapy": {
      "summary": "Starting on ***** and gemzar carboplatin asap, second line could use ***** or clinical trials (such as a FGFR inhibitor) or other ***** (such as eribulin or doxil) for more advanced line treatment",
      "Short term side_effects_discussed": "Not mentioned",
      "Long term side_effects_discussed": "Not mentioned"
    },
    "radiotherapy": {
      "summary": "Had adjuvant radiation",
      "Short term side_effects_discussed": "Not mentioned",
      "Long term side_effects_discussed": "Not mentioned"
    },
    "hormonal therapy": {
      "summary": "Not mentioned",
      "Short term side_effects_discussed": "Not mentioned",
      "Long term side_effects_discussed": "Not mentioned"
    },
    "bone therapy": {
      "summary": "Not mentioned",
      "Short term side_effects_discussed": "Not mentioned",
      "Long term side_effects_discussed": "Not mentioned"
    },
    "other treatment": {
      "summary": "Xeloda",
      "Short term side_effects_discussed": "Not mentioned",
      "Long term side_effects_discussed": "Not mentioned"
    }
  },
  "Medication_Plan": "I recommend starting on  and gemzar carboplatin asap. Second line she could use  or other  (such as eribulin or doxil) for more advanced line treatment.",
  "Therapy plan": "Start on ***** and gemzar carboplatin asap. Second line could use ***** or clinical trials (such as a FGFR inhibitor) or other options (such as eribulin or doxil) for more advanced line treatment.",
  "radiotherapy plan": {
    "radiotherapy": [
      "adjuvant radiation"
    ]
  },
  "Procedure_Plan": {
    "procedure_plan": "We recommend starting on ***** and gemzar carboplatin asap. Second line she could use ***** or other clinical trials (such as a FGFR inhibitor) or other ***** (such as eribulin or doxil) for more advanced line treatment."
  },
  "Imaging Plan": {
    "imaging_plan": "No imaging plan mentioned."
  },
  "Lab Plan": {
    "lab_plan": "The patient is to start on chemotherapy (gemzar carboplatin) asap, and second line treatment options include clinical trials or other treatments such as eribulin or doxil."
  },
  "Genetic_Testing_Plan": {
    "genetic_testing_plan": "No new genetic or molecular tests were planned during this visit."
  },
  "Referral": {
    "Nutrition": "anti inflammatory and /or diabetes risk reducing diet",
    "Genetics": "",
    "Specialty": "Medical Oncology/Hematology",
    "Others": "",
    "follow up": ""
  },
  "follow up/next visit": {
    "Next clinic visit": "Not specified"
  },
  "Advance care planning": {
    "Advance care": "There is no mention of advance care planning, advance directives, health-care proxy, or code status in the provided note."
  }
}
